Previous studies have historically shown that tacrolimus elevates levels of transforming growth factor-beta (TGF-β), thereby promoting cancer progression and metastatic disease in post-transplant hepatocellular carcinoma, human lung adenocarcinoma cells, and renal cell carcinoma [32]. Here, TGFB1 is linked to hereditary clear cell renal cell carcinoma.